Skip to content

Study · Systematic review · n = 583 · 2009

3 results

Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis.

Zhang YY, Chen EQ, Yang J, Duan YR, Tang H

Virology journal25 May 2009Cited by 15 (Europe PMC)

PMID19467157 (opens in a new tab)PMCIDPMC2693103 (opens in a new tab)DOI10.1186/1743-422x-6-63 (opens in a new tab)PepBankPUB-19467157
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

BackgroundCurrently, there is no evidence on the combination of lamivudine and thymosin alpha-1 on chronic hepatitis B patients. The aim of this study was to compare the effect of lamivudine monotherapy with that of lamivudine and thymosin alpha-1 combination therapy for the treatment of hepatitis B e antigen (HBeAg)-positive hepatitis B patients.ResultsWe searched PUBMED (from 1966 onwards), EMBASE (from 1966), CBMdisk (Chinese Biomedical Database, from 1978), CNKI (National Knowledge Infrastructure, from 1980), the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. Eight trials (583 patients in total) were identified. The lamivudine and thymosin alpha-1 combination treatment was significantly superior to lamivudine treatment in terms of ALT normalization rate (80.2% vs. 68.8%, P = 0.01), virological response rate (84.7% vs. 74.9%, P = 0.002), and HBeAg seroconversion rate (45.1% vs. 15.2%, P < 0.00001).ConclusionAmong HBeAg-positive patients, thymosin alpha-1 and lamivudine combination therapy may be more effective than lamivudine monotherapy, providing superior rates of biochemical response, virological response, and HBeAg seroconversion.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In HBeAg-positive chronic hepatitis B patients, thymosin alpha‑1 plus lamivudine gave a higher ALT normalization rate than lamivudine alone.

    In plain wordsIn people with chronic hepatitis B, adding thymosin alpha‑1 to lamivudine normalized liver enzyme ALT more often than lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseALT normalization rate
    Study

    n = 583

    Comparator
    Lamivudine monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    ALT normalization rate
    80.2%
    lamivudine plus thymosin alpha-1
    ALT normalization rate
    68.8%
    lamivudine alone

    Source sentences

    Summary
    The lamivudine and thymosin alpha-1 combination treatment was significantly superior to lamivudine treatment in terms of ALT normalization rate (80.2% vs. 68.8%, P = 0.01), virological response rate (84.7% vs. 74.9%, P = 0.002), and HBeAg seroconversion rate (45.1% vs. 15.2%, P < 0.00001).
    1 context sentence
    Summary · context
    Eight trials (583 patients in total) were identified.
  2. 02HumanSystematic reviewEfficacy outcome

    In HBeAg-positive chronic hepatitis B patients, thymosin alpha‑1 plus lamivudine gave a higher virological response rate than lamivudine alone.

    In plain wordsIn people with chronic hepatitis B, adding thymosin alpha‑1 to lamivudine gave more virus control than lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseVirological response rate
    Study

    n = 583

    Comparator
    Lamivudine monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    Virological response rate
    84.7%
    lamivudine plus thymosin alpha-1
    Virological response rate
    74.9%
    lamivudine alone

    Source sentences

    Summary
    The lamivudine and thymosin alpha-1 combination treatment was significantly superior to lamivudine treatment in terms of ALT normalization rate (80.2% vs. 68.8%, P = 0.01), virological response rate (84.7% vs. 74.9%, P = 0.002), and HBeAg seroconversion rate (45.1% vs. 15.2%, P < 0.00001).
    1 context sentence
    Summary · context
    Eight trials (583 patients in total) were identified.
  3. 03HumanSystematic reviewEfficacy outcome

    In HBeAg-positive chronic hepatitis B patients, thymosin alpha‑1 plus lamivudine gave a higher HBeAg seroconversion rate than lamivudine alone.

    In plain wordsIn people with chronic hepatitis B, adding thymosin alpha‑1 to lamivudine led to HBeAg seroconversion more often than lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBeAg seroconversion rate
    Study

    n = 583

    Comparator
    Lamivudine monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBeAg seroconversion rate
    45.1%
    lamivudine plus thymosin alpha-1
    HBeAg seroconversion rate
    15.2%
    lamivudine alone

    Source sentences

    Summary
    The lamivudine and thymosin alpha-1 combination treatment was significantly superior to lamivudine treatment in terms of ALT normalization rate (80.2% vs. 68.8%, P = 0.01), virological response rate (84.7% vs. 74.9%, P = 0.002), and HBeAg seroconversion rate (45.1% vs. 15.2%, P < 0.00001).
    1 context sentence
    Summary · context
    Eight trials (583 patients in total) were identified.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.